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Abstract: Gastric lipase is one of the prepancreatic lipases found in some mammalian 
species and in humans. Our knowledge of the hormonal regulation of gastric lipase secretion 
in children and adolescents is still very limited. The aim of this study was to compare the 
activity of human gastric lipase (HGL) in gastric juice in healthy adolescents and in patients 
with gastritis. The adolescents were allocated to three groups: the first including patients 
with Helicobacter pylori gastritis (HPG; n = 10), the second including patients with 
superficial gastritis caused by pathogens other than H. pylori (non-HPG; n = 14) and the 
control group including healthy adolescents (n = 14). Activity of HGL was measured in 
gastric juice collected during endoscopy. Plasma concentrations of cholecystokinin (CCK), 
glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) were 
measured in all adolescents. Activity of HGL in the non-HPG group was significantly lower 
than in the HPG group (p < 0.005) and the control group (p < 0.005). Mean plasma GIP 
levels in the control group were lower than in the non-HPG group (p < 0.003) and the HPG 
group (p < 0.01). We conclude that the regulation of HGL secretion by GLP-1 and CCK is 
altered in patients with gastritis. Moreover, GIP is a potent controller of HGL activity, both 
in healthy subjects and in patients with gastritis. 
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1. Introduction 
Gastric lipase is one of the mammalian preduodenal lipases (also termed prepancreatic lipases) [1–3]. 
Immunochemical studies revealed that human gastric lipase (HGL) is secreted by the chief (zymogen) 
cells of gastric mucosa [4]. HGL takes part in digestion of fats, and it accounts for approximately 40% of 
preduodenal lipolysis. In newborns, the activity of pancreatic lipase is low, and therefore, the bile salt 
stimulated lipase (BSSL), present in breast milk, and HGL are important for digestion of fats in this 
period of life [5]. In older children and in adults, HGL may also be important. It has been suggested that 
products of gastric hydrolysis of dietary triacylglycerol may promote lipolysis and regulate intestinal 
function [6]. Supplementation with acid-stable gastric lipase seems to be one of the potential therapies of 
pancreatic insufficiency [7,8]. Supplementation with exogenous gastric lipase has no adverse effects 
typical for supplementation with pancreatic lipase, like fibrosing colonopathy [9,10]. A recent study 
using an animal model suggests that inhibition of gastric lipase might be used to treat obesity and 
improve lipid profile [11]. It has been suggested that in healthy subjects, the regulatory peptides, like 
glucagon-like peptide-1 (GLP-1) and cholecystokinin (CCK), may influence secretion and/or activity of 
HGL [12]. Another peptide taking part in the regulation of the upper gastrointestinal function is 
glucose-dependent insulinotropic peptide (GIP), but we have not identified any data on the effects of 
GIP on gastric lipase secretion. Moreover, little is known about the regulation of HGL secretion in 
patients with gastric disorders, including gastritis, which is the most common gastric condition. 
Therefore, the aim of our study was to evaluate the activity of HGL in gastric juice collected from 
adolescents with superficial gastritis caused by Helicobacter pylori and with superficial gastritis caused 
by other factors, as well as from healthy subjects. In addition, plasma concentrations of major 
enterogastrones, GLP-1, CCK and GIP, which are potential regulators of HGL secretion/activity, were 
measured in all the adolescents taking part in the study. 
2. Experimental Section 
2.1. Groups of Patients 
Thirty eight adolescents aged 16 ± 3 years hospitalized in the University Children’s Hospital of 
Krakow were included in the study. The protocol was approved by the local Bioethics Committee. 
Written informed consent was obtained from all patients and their guardians prior to the participation in 
the study. 
The adolescents were allocated to three groups based on the results of gastroscopy, histology of the 
biopsy material and urease test for H. pylori. The group of patients with H. pylori gastritis (HPG, n = 10) 
included the patients with gastritis, in whom the diagnosis was based on macroscopic findings in 
gastroscopy and confirmed by histological methods, including a positive urease test and positive 
histological assessment for H. pylori using Giemsa stain. The group of patients with gastritis caused by 
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factors other than H. pylori (non-HPG, n = 14) included the patients with superficial gastritis, in whom 
the diagnosis was based on macroscopic findings in gastroscopy and confirmed by histological methods, 
including a negative urease test and negative histological assessment for H. pylori using Giemsa stain. 
The control group (CG, n = 14) included adolescents with no macroscopic abnormalities on gastroscopy 
and with normal histology of the biopsy samples. 
Height and body weight measurements were performed by an anthropometrist. The Body Mass Index 
(BMI) and BMI percentiles were calculated using online BMI calculators for patients ≤20 years of age. 
2.2. Gastric Juice Collection Method 
For 7 days before the gastroscopy, the patients did not receive any treatment that may have stimulated 
or inhibited the production of gastric juice. Gastric juice was collected during routine gastroscopy using 
the trapping method. Immediately after the gastroscope was introduced into the stomach, a 3 mL sample 
of gastric juice was suctioned via the auxiliary channel of the gastroscope and collected in a sterile vial. 
The samples were then centrifuged at 5000× g for 15 min at 4 °C to remove cell debris and other 
contaminations. Subsequently, the pH of the supernatant was measured, and the samples were frozen at 
−20 °C until assayed. 
2.3. Laboratory Tests 
2.3.1. Measurements of pH 
Measurements of the pH of the collected samples were performed using the InLab Micro  
electrode (Mettler Toledo; Schwarzenbach, Switzerland) for microsamples, connected to the Seven easy 
pH-meter (Mettler Toledo, Schwarzenbach, Switzerland). 
2.3.2. Measurements of Human Gastric Lipase Activity in Gastric Juice 
HGL activity in gastric juice was determined using the colorimetric method with 10 nM methanol 
solution of p-nitrophenyl caprylate. Twenty microliters of 10 mM p-nitrophenyl caprylate solution was 
added to 1 mL of centrifuged gastric juice. Absorbance was measured continuously at controlled 
conditions of pH 4.5 and 25 °C using a spectrophotometer with a thermostatic cuvette and continuous 
absorbance reading at 420 nm in a 1-cm path-length cell. A control assay without the enzyme was 
performed for each HGL activity measurement under the same conditions. The obtained value, 
corresponding to the autohydrolysis of the substrate, was subtracted from the calculation of HGL 
activity in samples. The amount of p-nitrophenol formed from p-nitrophenyl caprylate was calculated to 
assess the activity of HGL (1 μmol of p-nitrophenyl corresponding to one unit (U) of enzyme activity). 
2.3.3. Measurements of Peptide Concentrations in Blood 
Fasting blood samples for hormone measurements were collected to chilled glass tubes containing 
EDTA (4 mg) and aprotinin (Sigma-Aldrich, St. Louis, MO, USA) (0.2 TIU (trypsin inhibitor unit)) in 
the morning, shortly before the gastroscopy. Immediately after the sampling, the tubes were transported 
in ice to the laboratory. Blood was centrifuged at +4 °C for 10 min at 3000× g. Plasma samples were 
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stored at −20 °C until assayed. Concentrations of peptides were determined by radioimmunoassay (RIA) 
using commercial kits—CCK (Eurodiagnostica, Sweden), GIP and GLP-1 (7–37) (Phoenix 
Pharmaceuticals, Inc., Burlingame, CA, USA). The extraction of CCK from plasma was carried out 
according to the following procedure: plasma (1 mL) was mixed with 96% ethanol (2 mL) followed by 
20 min centrifugation at +4 °C and 7000× g. The supernatant was evaporated in the stream of the 
nitrogen. The dry residue was dissolved in the RIA buffer immediately before the assay. Plasma samples 
for GIP and GLP-1 assays were extracted on the Sep-pak C-18 columns (Waters Corporation, Milford, 
MA, USA). Prior to the extraction, the plasma samples were acidified with 1% TFA (Sigma-Aldrich,  
St. Louis, MO, USA) (1:1, v/v), followed by 20 min centrifugation at +4 °C and 7000× g. The 
supernatant was applied on the column and washed three times with 3 mL 1% TFA solution. The 
peptides were then eluted off with 60% acetonitrile solution (3 mL) (Spectrosol, England) in 1% TFA. 
The eluate was evaporated under nitrogen at 40 °C. The dry residue was dissolved in the appropriate RIA 
buffer immediately before the assay. The recovery test using the control samples containing the known 
amounts of peptides were 92% ± 3% for CCK, 84% ± 4% for GIP and 84% ± 4% for GLP-1. 
2.4. Statistical Analysis 
All the results are reported as mean values ± SD. Statistical analysis was carried out using the Student’s 
t-test. Correlation analysis was performed using the Statistica 10 (Statsoft) and Excel (Microsoft Office 
Home and Student 2010) software. A p-value of 0.05 was considered statistically significant. 
3. Results 
3.1. Anthropometric Measurements 
There were no significant differences between the study groups with respect to age, body weight  
and BMI. 
3.2. pH 
We found no differences of acidity (pH) of the gastric juice between the study groups (non-HPG  
1.55 ± 0.27; HPG 1.53 ± 0.20; CG 1.5 ± 0.25). 
3.3. HGL Activity 
The mean activity of HGL in gastric juice in the non-HPG group (0.247 ± 0.09 mU/L ) was  
significantly lower than in the two remaining groups (HPG—0.466 ± 0.151 mU/L, p < 0.0005;  
CG—0.504 ± 0.191 mU/L, p < 0.0001; Figure 1). The differences of HGL activity between CG and HPG 
groups were not significant (p = 0.33). 
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Figure 1. The mean activity of human gastric lipase (HGL) and mean concentrations of 
cholecystokinin (CCK), glucagon-like peptide-1 (GLP-1) and glucose-dependent 
insulinotropic peptide (GIP) in the study groups (non-HPG—non-Helicobacter pylori 
gastritis group, HPG—Helicobacter pylori gastritis group, CG—control group). 
 
3.4. Peptide Concentrations 
Mean plasma levels of GIP were lower in the control group (117 ± 29 pmol/L) than in the non-HPG 
group (179 ± 69 pmol/L, p < 0.003) and the HPG group (155 ± 40 pmol/L, p < 0.01) (Figure 1).  
No statistically significant differences of GIP concentrations between the non-HPG and HPG groups  
were observed (p = 0.21). Mean plasma concentrations of CCK were highest in the HPG group  
(0.54 ± 0.14 ng/mL). They were significantly higher than in the non-HPG group (0.35 ± 0.2 ng/mL,  
p < 0.01) and the control group (0.39 ± 0.19 ng/mL, p < 0.05) (Figure 1). The differences of CCK 
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concentrations between the CG and non-HPG groups were not significant (p = 0.34). Mean plasma 
concentrations of GLP-1 were similar in all study groups (non-HPG—5.7 ± 1.6 pmol/L; HPG and  
CG—5.2 ± 2.2 pmol/L; p-values for statistical comparisons: CG vs. non-HPG, p = 0.23; CG vs. HPG,  
p = 0.33; non-HPG vs. HPG, p = 0.45; Figure 1). 
3.5. Correlations 
The analysis of pooled results performed in all three groups revealed significant correlation between 
the activity of HGL and the plasma concentration of GIP (r = −0.50; p < 0.01) (Figure 2). Similarly, 
statistically significant correlation was observed between the non-HPG group (r = −0.69; p < 0.001) and 
the control group (r = −0.39, p < 0.05). In the HPG group, a negative correlation was also found, but it 
did not reach statistical significance. Significant positive correlation between HGL activity and CCK 
concentrations was also observed in the control group (r = 0.40; p < 0.05). No other statistically 
significant correlations between the activity of HGL and the concentrations of the measured peptides 
were found within the study groups, as well as in the whole study population. 
Figure 2. Correlation between activity of HGL and concentration of GIP in all studied patients. 
 
4. Discussion 
The only available data on the activity of HGL in patients with gastritis were published by Sarles et al. 
in 1992 [13]. The authors studied a group of 55 children aged from zero to 17 years, including only  
nine patients with gastritis. Unfortunately, the details of the age of the patients and the etiology and 
severity of gastritis were not provided in the publication. Sarles et al. reported that in seven children with 
gastritis, the activity of HGL was normal, while in the two remaining children, only a trace HGL activity 
was found. They concluded that the activity of HGL is only rarely reduced in patients with gastritis [13]. 
In our study, the age of the patients was in a similar range (adolescents), and all of them had gastritis. 
Moreover, all our patients were tested for H. pylori infection. Therefore, our results are only partially 
comparable to the data published by Sarles et al. [13]. We have found that in the patients with H. pylori 
gastritis, the mean activity of HGL in gastric juice was similar to that found in healthy subjects. 
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However, the activity of HGL in patients with non-H. pylori gastritis was significantly lower than in the 
control group (p < 0.0001; Figure 1). 
Several factors may influence the secretion of HGL. Firstly, the differences in the acidity of gastric 
juice should be taken into account. HGL is an acid-stable lipase, with the optimum activity at the pH 
values of approximately five [14]. However, in our study, pH values had no effect on the activity of 
HGL, because in all study groups, the pH of gastric juice was similar. Another explanation could be 
duodenal reflux, which may cause the displacement of bile into gastric contents. Reflux was observed in 
more than half of the patients with gastritis caused by H. pylori. Contamination of gastric contents with 
bile salts should decrease the activity of HGL, as taurocholate is known to be an inhibitor of  
HGL [15,16]. However, conflicting data were published in the literature, showing that low levels of 
taurocholate may actually increase the activity of HGL [17]. Another explanation of this phenomenon 
may be an alteration of endogenous control mechanisms of HGL secretion. In healthy adults, gastrin 
increases the secretion of HGL [18]. Wojdemann et al. and Borovicka et al. observed that GLP-1 and 
CCK inhibited the secretion of HGL [12,19,20]. They found that an intravenous infusion of GLP-1 
imitating the postprandial levels of this peptide reduced both secretion and activity of HGL in  
humans [19]. On the other hand, an infusion of loxiglumide (CCK-A receptor antagonist) increased the 
secretion of HGL [20]. In our study, the concentrations of CCK, GLP-1 (amide) and GIP were measured. 
We found no differences in GLP-1 concentrations between the study groups and no correlation between 
the levels of GLP-1 and the activity of HGL. Surprisingly, the concentrations of CCK, which was 
described by Borovicka et al. as an inhibitor of HGL secretion, as well as a stimulator of pancreatic 
lipase secretion, showed positive correlation with the activity of HGL [20]. This suggests that either the 
regulation of HGL secretion by GLP-1 and CCK is abnormal in gastritis or there exists another factor 
with higher potential for regulation of the secretion and activity of HGL. The small size of our study may 
be a source of bias, though it must be noted that Borovicka studied six subjects only [20]. To date, GIP 
has not been analyzed as a factor influencing the secretion or activity of HGL. However, GIP is a known 
activator of lipoprotein and pancreatic lipases [21,22]. The negative correlation between the 
concentrations of GIP and the activity of HGL in the whole study population suggests that GIP has an 
inhibitory effect on HGL secretion similar to other enterogastrones (CCK and GLP-1). In addition, GIP 
could be one of the main regulators of the secretion and activity of HGL in healthy subjects and in 
patients with gastritis. 
The role of HGL in the digestion of lipids is significant, due to its activity in a wide range of pH 
values. Petersen et al. observed lipolytic activity of HGL in solutions of high acidity (pH 2.8) [23]. HGL 
is also active in the duodenum, where it is responsible for hydrolysis of 7.5% of triglycerides [24]. 
Vaquero et al. showed in an animal model that inhibition of gastric lipase caused a moderate reduction of 
fat absorption, resulting in reduction of weight gain, as well as triglyceride and cholesterol levels [11]. 
These data suggest that HGL is a potential target for the treatment of obesity, and therefore, the results of 
our study may have implications for future research on the treatment of obesity. 
5. Conclusions 
1. The activity of HGL is reduced in patients with non-H. pylori gastritis. 
2. Regulation of HGL activity by GLP-1 and CCK is abnormal in patients with gastritis. 
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3. GIP is a potent regulator of HGL activity. 
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